Literature DB >> 8691926

Does growth-hormone supplementation affect adult height in Turner's syndrome?

S P Taback1, R Collu, C L Deal, H J Guyda, S Salisbury, H J Dean, G Van Vliet.   

Abstract

BACKGROUND: By comparison with historical controls, the effect of treatment with growth hormone on adult height in Turner's syndrome was initially reported as uniformly and strongly positive. Because randomised controlled trials are not near completion, we report our experiences in an open study.
METHODS: We examined adult height, projected and attained, in 31 patients (17 treated with subcutaneous recombinant human growth hormone, up to 15 mg a week, outside of a controlled trial and 14 untreated contemporaries).
FINDINGS: Contingency table analysis of attained versus projected height showed significantly higher values in treated patients although only 4 of 17 had final heights of 5 cm or more over projection. Patients' and treatment variables (height, bone-age delay, oestrogen replacement) that interfere with adult height projection confounded the analysis of adult height data.
INTERPRETATION: Girls with Turner's syndrome should be counselled cautiously about the expectation of a strongly positive effect of treatment on adult height. Completion of the randomised controlled trials to adult height is needed to establish the effect of growth-hormone supplementation on adult height in Turner's syndrome and the psychological effect of treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691926     DOI: 10.1016/s0140-6736(96)01267-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Long-term results of growth hormone therapy in Turner syndrome.

Authors:  J H Bramswig
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

Review 2.  Turner syndrome and GH treatment: the state of the art.

Authors:  A M Pasquino
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

3.  Adult height in sixty girls with Turner syndrome treated with growth hormone matched with an untreated group.

Authors:  A M Pasquino; I Pucarelli; M Segni; L Tarani; V Calcaterra; D Larizza
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

Review 4.  The use of somatropin (recombinant growth hormone) in children of short stature.

Authors:  Ameeta Mehta; Peter C Hindmarsh
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 5.  Advances in endocrinology.

Authors:  P E Clayton; V Tillmann
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

6.  Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone.

Authors:  T C Sas; S M de Muinck Keizer-Schrama; T Stijnen; A van Teunenbroek; A C Hokken-Koelega; J J Waelkens; G G Massa; T Vulsma; W J Gerver; H M Reeser; H E Delemarre-van de Waal; M Jansen; S L Drop
Journal:  Arch Dis Child       Date:  1999-01       Impact factor: 3.791

Review 7.  Value of growth hormone treatment in Turner's syndrome.

Authors:  P Saenger
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

8.  Bone age is the best predictor of growth response to recombinant human growth hormone in Turner's syndrome.

Authors:  Nagwa Abdallah Ismail; Nermeen Salah Eldin Metwaly; Fatma Ahmed El-Moguy; Mona Hassan Hafez; Soha M Abd El Dayem; Tarek Mohamed Farid
Journal:  Indian J Hum Genet       Date:  2010-09

9.  Height predict incident non-alcoholic fatty liver disease among general adult population in Tianjin, China, independent of body mass index, waist circumference, waist-to-height ratio, and metabolic syndrome.

Authors:  Shubham Kumari; Xuena Wang; Yunyun Liu; Yeqing Gu; Yuhan Huang; Qing Zhang; Li Liu; Ge Meng; Hongmei Wu; Shaomei Sun; Xing Wang; Ming Zhou; Qiyu Jia; Guolin Wang; Kun Song; Kaijun Niu
Journal:  BMC Public Health       Date:  2020-03-24       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.